Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mannatide Combined With CAPOX and Tislelizumab in Advanced Gastric/GEJ Adenocarcinoma
NCT07655661Phase 2Not yet recruiting
- Sponsor
- MingSight Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
A Phase 2 trial of mannatide in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by MingSight Pharmaceuticals. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
mannatide
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07655661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07655661.